NGM Biopharmaceuticals, Inc (NGM)

Etorro trading 970x250
NGM Biopharmaceuticals, Inc (NGM) Logo

About NGM Biopharmaceuticals, Inc

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company’s product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 2b clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase 2 clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438 for the development of treatment of cancer. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California. Address: 333 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

NGM Biopharmaceuticals, Inc News and around…

Latest news about NGM Biopharmaceuticals, Inc (NGM) common stock and company :

Hedge Funds Are Crazy About NGM Biopharmaceuticals, Inc. (NGM)
12 Jan, 2022 Yahoo! Finance

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs
10 Jan, 2022 Yahoo! Finance

After a transformative year in 2021, NGM Bio enters 2022 with a diverse pipeline of seven disclosed programs, including four programs in Phase 2 trials and a wholly-owned oncology portfolioAnticipated milestones in 2022 include: Topline data readout from the Phase 2 CATALINA trial of NGM621 in patients with geographic atrophy expected in the fourth quarter of 2022Phase 1a data readout from the ongoing trial of NGM707 monotherapy in patients with advanced solid tumors expected in the second half

NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
06 Jan, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13th at 7:30 AM PST/10:30 AM EST. A live audio webcast of the pres

Peek Under The Hood: RYJ Has 39% Upside
21 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $82.41 per unit.

NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)
06 Dec, 2021 Yahoo! Finance

NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the potential of NGM707 in combination with KEYTRUDA for the treatment of patients with advanced or metastatic solid tumorsNGM707 is part of NGM’s wholly-owned portfolio of immuno-oncology programs focused on releasing myeloid checkpoints to reprogram myeloid cells to reverse immune suppressionILT2 and ILT4, upregulated in certain tumor types, are believed to serve as myeloid checkpoints, helping tumors e

NGM Biopharmaceuticals (NGM) Shares Cross Below Book Value
23 Nov, 2021 FinancialContent

In trading on Tuesday, shares of NGM Biopharmaceuticals Inc (NGM) crossed below their last reported book value — defined as common shareholder equity per share — of $19.00, changing hands as low as $18.72 per share. NGM Biopharmaceuticals Inc shares are currently trading down about 5.5% on the day..

NGM Biopharmaceuticals (NASDAQ:NGM) shareholders have endured a 15% loss from investing in the stock a year ago
22 Nov, 2021 Yahoo! Finance

Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...

Analysts Expect FYC To Hit $89
19 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Growth AlphaDEX Fund ETF (FYC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $89.33 per unit.

NGM Bio to Participate in Upcoming Investor Conferences
09 Nov, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming 2021 virtual investor conferences: Stifel 2021 Virtual Healthcare Conference Monday, November 15, 2021, 2:40pm ET

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Lags Revenue Estimates
04 Nov, 2021 Yahoo! Finance

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 2.63% and -1.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
04 Nov, 2021 Yahoo! Finance

Presented preliminary Phase 1a/1b trial findings at ESMO 2021 for NGM120, a GFRAL antagonist antibody product candidate, that showed the drug was well tolerated in advanced solid tumors and provided encouraging initial signals of anti-cancer activity in patients with metastatic pancreatic cancerInitiated Phase 1/2 clinical study of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in patients with advanced solid tum

NGM Biopharmaceuticals (NGM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
04 Nov, 2021 Yahoo! Finance

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hedge Funds Are Piling Into NGM Biopharmaceuticals, Inc. (NGM)
29 Oct, 2021 Yahoo! Finance

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]

Sum Up The Pieces: FYC Could Be Worth $87
19 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Growth AlphaDEX Fund ETF (FYC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $87.30 per unit.

Is Good News Enough for You to Buy NGM on the Dip?
06 Oct, 2021 FinancialContent

A drop in the overall market provides an opportunity for investors to pounce.

Raymond James: These 3 Stocks Could Deliver at Least 40% Gains
30 Sep, 2021 Yahoo! Finance

Are the good times for stocks ending? Maybe so, and maybe not; the NASDAQ and the S&P are showing year-to-date gains between 14% and 17%, even after slipping from their all-time highs. The one thing that’s clear is, volatility is higher in the market. But as always in the market, increased risk for some can equal increased opportunities for others. Raymond James stock analysts have been busy picking out the stocks they see as winners, able to swim in the stream of increasingly difficult economic

Analysts Anticipate 22% Upside For The Holdings of IHE
17 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

10 Biggest Price Target Changes For Friday
17 Sep, 2021 FinancialContent

UBS cut FedEx Corporation (NYSE: FDX) price target from $397 to $380. FedEx shares fell 0.2% to $258.00 in pre-market ...

NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial
16 Sep, 2021 FinancialContent

NGM Biopharmaceuticals Inc(NASDAQ: NGM)announced preliminary findingsfrom its ongoing Phase 1a/1b dose-escalation ...

NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
16 Sep, 2021 FinancialContent
Ngm Biopharmaceuticals Insider Trades $775.31 Thousand In Company Stock
15 Sep, 2021 Yahoo! Finance

Jin-Long Chen, Chief Scientific Officer at Ngm Biopharmaceuticals (NASDAQ:NGM), made a large insider sell on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Chen sold 30,000 shares of Ngm Biopharmaceuticals at a price of $26.08 per share. The total transaction amounted to $775,306. Chen still owns a total of 929,449 of Ngm Biopharmaceuticals worth, $24,286,502. Ngm Biopharmaceuticals shares are tr

72 Biggest Movers From Yesterday
14 Sep, 2021 FinancialContent

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from ...

Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
13 Sep, 2021 FinancialContent

Raymond James has upgradedNGM Biopharmaceuticals Inc(NASDAQ: NGM) toStrong Buy from Outperformwith a price ...

45 Stocks Moving In Monday's Mid-Day Session
13 Sep, 2021 FinancialContent

Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news ...

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021
13 Sep, 2021 FinancialContent

Upgrades For Bank of America Corp (NYSE:BAC), Odeon Capital upgraded the previous rating of Hold to Buy. For the second ...

10 Biggest Price Target Changes For Monday
13 Sep, 2021 FinancialContent

Keybanc lowered the price target on FedEx Corporation (NYSE: FDX) from $370 to $350. FedEx shares rose 0.6% to $259.00 in pre-market ...

60 Biggest Movers From Friday
13 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported ...

Noteworthy Friday Option Activity: NGM, RFL, TNL
10 Sep, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in NGM Biopharmaceuticals Inc (NGM), where a total of 3,450 contracts have traded so far, representing approximately 345,000 underlying shares. That amounts to about 149.5% of NGM's average daily trading volume over the past month of 230,750 shares..

41 Stocks Moving In Friday's Mid-Day Session
10 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its ...

12 Health Care Stocks Moving In Thursday's After-Market Session
09 Sep, 2021 FinancialContent

Gainers IVERIC bio (NASDAQ:ISEE) shares moved upwards by 31.76% to $11.45 during Thursday's after-market session. Trading volume for ...

NGM Biopharmaceuticals, Inc (NGM) is a NASDAQ Common Stock listed in , ,

970x250